Colorescience announced the appointment of former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for Colorescience, also formerly of SkinMedica, will remain in her current position.
In addition, former SkinMedica Senior Vice President of Corporate Development, Ted Ebel, joins Colorescience as Chief Business Officer.
Fisher has more than 25 years experience in the pharmaceutical and biotechnology industries. Prior to SkinMedica, she was Chief Operating Officer of Acorda Therapeutics with responsibility for corporate strategy and business development, sales and marketing, and manufacturing. Previously, she was VP, Strategic Healthcare and Commercial Operations for Cephalon, with responsibility for global commercial operations. Earlier, she was at Immunex and Boehringer Ingelheim. She is a member of the Board of aesthetics firm, Zeltiq (ZLTQ), and a Trustee of the Board of the Neuroscience Nursing Foundation.
Prior to joining SkinMedica, Ebel held senior management positions in Corporate Development and Strategy at CancerVax Corporation, where he was responsible for mergers and acquisitions, in-licensing and out-licensing activities. Prior to CancerVax, Ebel was Vice President, Strategic Ventures at MP3.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.